Hovione is recognized as a Top Employer 2023
This certification is a recognition of Hovione´s resolve to put people first, and a validation that the investment in HR excellence is delivering.
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
This certification is a recognition of Hovione´s resolve to put people first, and a validation that the investment in HR excellence is delivering.
Hovione has once again solidified its position as a top employer.
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Business Wire, September 23, 2020
The agreement furthers Hovione´s ability to bring the benefits of continuous tableting, including reduced time to market and increased supply chain flexibility, to pharmaceutical customers globally
CheManager, 20 October 2020